<DOC>
	<DOCNO>NCT00405951</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogneic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell . This multi-center , open-label , Phase I/II study obatoclax administer combination docetaxel 3-week cycle patient relapse refractory Non-Small Cell Lung Cancer . Treatment may administer outpatient basis . No investigation commercial agent therapy describe herein may administer intent treat patient 's malignancy . Supportive care measure include direct control symptom result Non-Small Cell Lung Cancer allow .</brief_summary>
	<brief_title>Safety Efficacy Obatoclax Mesylate ( GX15-070MS ) Combination With Docetaxel Treatment Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Pathological confirmation NonSmall Cell Lung Cancer ( NSCLC ) Must previously treat single platinumbased chemotherapy regimen show evidence disease progression ; limitation Must normal organ function Must willing submit blood sampling plan PK PD analysis Must ability understand willingness sign write informed consent form No agent therapy administer intent treat malignancy Patients prior exposure obatoclax docetaxel Uncontrolled , intercurrent illness Pregnant woman woman breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>